BACKGROUND: Systemic administration of sclerostin neutralizing antibody has led to increased bone formation in animal models of osteoporosis. The purpose of this study was to determine if systemic administration of sclerostin neutralizing antibody could increase the healing response in a critical-sized femoral defect in rats. METHODS: Critical-sized femoral defects were created in Lewis rats, and the rats were randomized into four groups. The sclerostin antibody (Scl-Ab) treatment groups included the continuous Scl-Ab group (twenty-one animals), the early Scl-Ab group (fifteen animals), and the delayed Scl-Ab group (fifteen animals), which received sclerostin antibody (25 mg/kg) twice weekly for weeks 0 through 12; weeks 0 through 2; and weeks 2 through 4; respectively. Twenty-one animals in the control group received vehicle from weeks 0 through 12. In a subsequent study, bone turnover markers were measured at zero, two, six, and twelve weeks after surgery in rats receiving vehicle or sclerostin neutralizing antibody for twelve weeks (fifteen rats per group). The quality of bone formed was evaluated with radiographs, microcomputed tomography, biomechanical testing, and histologic and histomorphometric analysis. RESULTS: In the primary study, four of fifteen defects in the continuous (zero to twelve-week) Scl-Ab group, three of fifteen defects in the early (zero to two-week) Scl-Ab group, and four of fifteen defects in the delayed (two to four-week) Scl-Ab group healed at twelve weeks, while none of the defects healed in the control group. In both studies, treatment with sclerostin antibody for twelve weeks demonstrated a significant increase in new bone formation (p < 0.05) compared with the control group. The three treatment groups did not differ significantly with respect to the healing rates and the quality of new bone formed in the defect. The serum markers of bone formation were significantly elevated in the animals in the continuous Scl-Ab group (p < 0.05) compared with the controls. CONCLUSIONS: Administration of sclerostin neutralizing antibody led to increased bone formation, resulting in complete healing of femoral defects in a small subset of rats, with a majority of the animals not healing the defect by twelve weeks.
BACKGROUND: Systemic administration of sclerostin neutralizing antibody has led to increased bone formation in animal models of osteoporosis. The purpose of this study was to determine if systemic administration of sclerostin neutralizing antibody could increase the healing response in a critical-sized femoral defect in rats. METHODS: Critical-sized femoral defects were created in Lewis rats, and the rats were randomized into four groups. The sclerostin antibody (Scl-Ab) treatment groups included the continuous Scl-Ab group (twenty-one animals), the early Scl-Ab group (fifteen animals), and the delayed Scl-Ab group (fifteen animals), which received sclerostin antibody (25 mg/kg) twice weekly for weeks 0 through 12; weeks 0 through 2; and weeks 2 through 4; respectively. Twenty-one animals in the control group received vehicle from weeks 0 through 12. In a subsequent study, bone turnover markers were measured at zero, two, six, and twelve weeks after surgery in rats receiving vehicle or sclerostin neutralizing antibody for twelve weeks (fifteen rats per group). The quality of bone formed was evaluated with radiographs, microcomputed tomography, biomechanical testing, and histologic and histomorphometric analysis. RESULTS: In the primary study, four of fifteen defects in the continuous (zero to twelve-week) Scl-Ab group, three of fifteen defects in the early (zero to two-week) Scl-Ab group, and four of fifteen defects in the delayed (two to four-week) Scl-Ab group healed at twelve weeks, while none of the defects healed in the control group. In both studies, treatment with sclerostin antibody for twelve weeks demonstrated a significant increase in new bone formation (p < 0.05) compared with the control group. The three treatment groups did not differ significantly with respect to the healing rates and the quality of new bone formed in the defect. The serum markers of bone formation were significantly elevated in the animals in the continuous Scl-Ab group (p < 0.05) compared with the controls. CONCLUSIONS: Administration of sclerostin neutralizing antibody led to increased bone formation, resulting in complete healing of femoral defects in a small subset of rats, with a majority of the animals not healing the defect by twelve weeks.
Authors: Xiaodong Li; Kelly S Warmington; Qing-Tian Niu; Franklin J Asuncion; Mauricio Barrero; Mario Grisanti; Denise Dwyer; Brian Stouch; Theingi M Thway; Marina Stolina; Michael S Ominsky; Paul J Kostenuik; William S Simonet; Chris Paszty; Hua Zhu Ke Journal: J Bone Miner Res Date: 2010-07-16 Impact factor: 6.741
Authors: Mandeep S Virk; Osamu Sugiyama; Sang H Park; Sanjiv S Gambhir; Douglas J Adams; Hicham Drissi; Jay R Lieberman Journal: Mol Ther Date: 2011-02-22 Impact factor: 11.454
Authors: W Balemans; M Ebeling; N Patel; E Van Hul; P Olson; M Dioszegi; C Lacza; W Wuyts; J Van Den Ende; P Willems; A F Paes-Alves; S Hill; M Bueno; F J Ramos; P Tacconi; F G Dikkers; C Stratakis; K Lindpaintner; B Vickery; D Foernzler; W Van Hul Journal: Hum Mol Genet Date: 2001-03-01 Impact factor: 6.150
Authors: Michael S Ominsky; Chaoyang Li; Xiaodong Li; Hong L Tan; Edward Lee; Mauricio Barrero; Franklin J Asuncion; Denise Dwyer; Chun-Ya Han; Fay Vlasseros; Rana Samadfam; Jacquelin Jolette; Susan Y Smith; Marina Stolina; David L Lacey; William S Simonet; Chris Paszty; Gang Li; Hua Z Ke Journal: J Bone Miner Res Date: 2011-05 Impact factor: 6.741
Authors: Stephen J Gomberg; Rosanna L Wustrack; Nicola Napoli; Claude D Arnaud; Dennis M Black Journal: J Clin Endocrinol Metab Date: 2011-03-23 Impact factor: 5.958
Authors: Carola Krause; Olexandr Korchynskyi; Karien de Rooij; Stella E Weidauer; David J J de Gorter; Rutger L van Bezooijen; Sarah Hatsell; Aris N Economides; Thomas D Mueller; Clemens W G M Löwik; Peter ten Dijke Journal: J Biol Chem Date: 2010-10-15 Impact factor: 5.157
Authors: Venus Vakhshori; Sofia Bougioukli; Osamu Sugiyama; Hyunwoo P Kang; Amy H Tang; Sang-Hyun Park; Jay R Lieberman Journal: Bone Date: 2020-07-02 Impact factor: 4.398
Authors: Sharon M Moe; Neal X Chen; Christopher L Newman; Jason M Organ; Michaela Kneissel; Ina Kramer; Vincent H Gattone; Matthew R Allen Journal: J Bone Miner Res Date: 2015-03 Impact factor: 6.741
Authors: P R Gabbai-Armelin; M T Souza; H W Kido; C R Tim; P S Bossini; A M P Magri; K R Fernandes; F A C Pastor; E D Zanotto; N A Parizotto; O Peitl; A C M Renno Journal: J Mater Sci Mater Med Date: 2015-04-17 Impact factor: 3.896
Authors: Sofia Bougioukli; Ram Alluri; William Pannell; Osamu Sugiyama; Andrew Vega; Amy Tang; Tautis Skorka; Sang Hyun Park; Daniel Oakes; Jay R Lieberman Journal: Bone Date: 2019-08-06 Impact factor: 4.398